Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
/in Colorectal Cancer, Dendritic Cells, International PublicationsCurrent state and perspectives of dendritic cell vaccination in cancer immunotherapy
/in Dendritic Cells, International PublicationsImmunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice
/in Dendritic Cells, Hyperthermia, International PublicationsMannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
/in Dendritic Cells, Hypernephroma, International PublicationsCombination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
/in Dendritic Cells, International Publications, SCLCImmunization with antigen-pulsed dendritic cells significantly improves the immune response to weak self-antigens
/in Dendritic Cells, International PublicationsDendritic cell defects in patients with cancer: mechanisms and significance
/in Dendritic Cells, International PublicationsGenetically modified dendritic cells for therapeutic immunity
/in Dendritic Cells, International PublicationsGeneration of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
/in Chronic Leukemia, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer